Spectrum Prescription drugs to Report Next Quarter 2021 Financial Effects and Deliver Company Update

HENDERSON, Nev., August 05, 2021–(Organization WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical firm centered on novel and qualified oncology therapies, these days announced it will host a meeting contact to examine the next quarter 2021 fiscal success and provide a company update on Thursday, August 12, 2021 at 4:30 p.m. Jap/1:30 p.m. Pacific.

Meeting Simply call and Webcast:

Thursday, August 12, 2021 @ 4:30 p.m. Japanese/1:30 p.m. Pacific
Domestic: (877) 837-3910, Convention ID# 2398834
International: (973) 796-5077, Meeting ID# 2398834

The convention phone will also be readily available from the Trader Relations part of the company’s internet site at http://investor.sppirx.com/events-and-presentations and will be archived there soon soon after the reside party.

About Spectrum Prescription drugs, Inc.

Spectrum Prescription drugs is a biopharmaceutical business focused on attaining, producing, and commercializing novel and specific oncology therapies. Spectrum has a potent observe report of efficiently executing across the biopharmaceutical enterprise model, from in-licensing and obtaining differentiated prescription drugs, clinically building novel belongings, successfully attaining regulatory approvals and commercializing in a competitive health care market. Spectrum has a late-stage pipeline with novel belongings that serve regions of unmet want. This pipeline has the potential to rework the corporation in the near long term. For additional information on Spectrum Pharmaceuticals, please pay a visit to www.sppirx.com.

Forward-on the lookout assertion — This press release may well incorporate forward-seeking statements relating to potential occasions and the potential efficiency of Spectrum Prescription drugs that include risks and uncertainties that could induce precise success to differ materially. These statements are centered on management’s present beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s small business and its future, together with sure organization milestones, Spectrum’s capability to determine, get, create and commercialize a broad and diverse pipeline of late-stage scientific and professional goods, the timing and effects of Fda conclusions, and any statements that relate to the intent, perception, plans or anticipations of Spectrum or its management, or that are not a statement of historical truth. Hazards that could bring about true results to differ involve the possibility that Spectrum’s current and new drug candidates may perhaps not demonstrate safe and sound or productive, the risk that our current and new purposes to the Fda and other regulatory organizations might not get acceptance in a timely manner or at all, the possibility that our existing and new drug candidates, if accredited, may possibly not be much more powerful, safer or extra charge efficient than competing medications, the likelihood that our initiatives to acquire or in-license and build extra drug candidates may fall short, our dependence on third events for clinical trials, production, distribution and top quality handle and other pitfalls that are described in even more detail in the company’s experiences filed with the Securities and Trade Commission. The enterprise does not approach to update any this kind of forward-searching statements and expressly disclaims any obligation to update the details contained in this press launch except as essential by law.

SPECTRUM Pharmaceuticals, INC.® is a registered trademark of Spectrum Prescription drugs, Inc and its affiliate. REDEFINING Most cancers CARE™ and the Spectrum Pharmaceuticals logos are emblems owned by Spectrum Prescribed drugs, Inc. Any other emblems are the residence of their respective homeowners.

© 2021 Spectrum Prescribed drugs, Inc. All Legal rights Reserved

See supply variation on businesswire.com: https://www.businesswire.com/news/dwelling/20210805005110/en/

Contacts

Robert Uhl
Handling Director, Westwicke ICR
858.356.5932
[email protected]

Kurt Gustafson
Chief Fiscal Officer
949.788.6700
[email protected]